Corcept’s Voluntary Central Distribution Helps Korlym Evade REMS
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA required no REMS, though Korlym (mifepristone), also known as RU-486, will carry a boxed warning that the therapy for Cushing’s syndrome will terminate pregnancy; Corcept has set up distribution through a central pharmacy.
You may also be interested in...
Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.
Alzheimer’s, BRAIN Initiative Highlighted In $30 Billion NIH Budget Proposal
President Obama’s proposed $56 billion Opportunity, Growth and Security Initiative would add nearly $1 billion to the NIH budget but it is funded by offsets that are likely nonstarters in Congress.
Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.